VRTX34 Stock Price and Chart — BMFBOVESPA:VRTX34

Key facts today

Vertex Pharmaceuticals is close to finishing enrollment for a phase 3 study of its islet cell therapy, zimislecel, aimed at type 1 diabetes patients, with global submissions expected in 2026.

B of A Securities has increased the price target for Vertex Pharmaceuticals to $567.00 per share, up from the prior target of $555.00.

Analyze the impact Analyze the impact

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.